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A few U.S. veterans of the Gulf War have
fragments of depleted uranium (DU) metal
containing 0.75% titanium (Ti) embedded
in their tissues. During the war, several U.S.
tanks and ﬁghting vehicles were mistakenly
ﬁred upon and struck by munitions contain-
ing DU. Some of the crew members who
survived were left with multiple small frag-
ments of DU in their muscles and soft tis-
sues. The number, size, and location of the
fragments made surgical removal difficult.
Thirty-three of these survivors are in a med-
ical surveillance program of the U.S.
Department of Veterans Affairs to detect any
untoward health effects (1). Some of these
veterans had elevated concentrations of ura-
nium in the urine 7 years after wounding.
The persistence of these elevated urine con-
centrations suggested an ongoing mobiliza-
tion of uranium from the embedded
fragments, causing chronic systemic expo-
sure. This observation indicates that DU
fragments in the tissues are not inert foreign
bodies and may react differently in the body
from other embedded shrapnel.
Depleted uranium is used in projectiles
and armor by the U.S. military and several
other countries (2). Its high density (nearly
twice that of lead), ability to burn on impact
(pyrophoricity), self-sharpening properties,
and ready availability make DU an ideal
material for military purposes. DU is a
byproduct in the uranium enrichment
process of nuclear weapons production and
the nuclear fuel cycle. It is about 40% less
radioactive than natural uranium. The
chemical and physical properties of natural
uranium and DU are identical. To provide
the appropriate metallurgic properties for
military uses, DU is usually alloyed with
0.75% Ti. DU armor and projectiles were
effective in the Gulf War and Kosovo and
will undoubtedly be used in future combat.
A recent report by the International
Agency for Research on Cancer notes that
available studies are inadequate to permit
reliable and accurate estimates of the long-
term effects of DU in humans (3). However,
laboratory studies have indicated that DU
fragments may be carcinogenic. For exam-
ple, rats implanted in the muscles with 20
DU pellets (2.0 × 1.0 mm diameter)
excreted uranium in the urine for at least 18
months (4). Urine from these rats had
enhanced mutagenic activity in Salmonella
typhimurium strain TA98 and the Ames II
mixed strains (TA7001-7006) (5). The
mutagenicity increased in a dose- and time-
dependant manner with a strong positive
correlation with urinary uranium concentra-
tion. In addition, DU-uranyl chloride trans-
formed immortalized human osteoblastic
cells to the tumorigenic phenotype (6). DU-
uranyl chloride treatment produced a 9.6-
fold increase in neoplastic transformation fre-
quency compared with untreated control cells.
In comparison, nickel sulfate, a known human
carcinogen, produced a 7.1-fold increase in
transformation frequency. These ﬁndings of
mutagenesis and neoplastic transformation
suggest that DU may be carcinogenic.
To help clarify the potential carcino-
genicity of DU fragments in the soft tissues,
we conducted a long-term bioassay study
with implanted materials in rats. The study
included both positive and negative control
materials. The results indicate that DU frag-
ments cause localized tumors in rats and
that the carcinogenicity is correlated with
the size of the fragments. The study was
conducted in facilities fully accredited by the
Association for Assessment and Accreditation
of Laboratory Animal Care. In conducting
research using animals, the investigators
adhered to the Guide for the Care and Use of
Laboratory Animals (7). 
Materials and Methods
We determined the carcinogenicity of intra-
muscularly implanted DU (alloyed with
0.75% Ti) using a long-term bioassay study.
The sizes and shapes of the DU used were
similar to the range of sizes and shapes of DU
fragments embedded in soldiers wounded in
the Gulf War (8). We obtained cylindric DU
pellets from Manufacturing Sciences
Corporation (Oak Ridge, TN). Two sizes of
DU fragments were cut from DU foil
obtained from the same source. The physical
characteristics of the pellets and fragments
used in the study are shown in Table 1. The
mass of DU fragments used varied by a fac-
tor of 20, and the surface area varied by a
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In this study, we determined the carcinogenicity of depleted uranium (DU) metal fragments con-
taining 0.75% titanium in muscle tissues of rats. The results have important implications for the
medical management of Gulf War veterans who were wounded with DU fragments and who
retain fragments in their soft tissues. We compared the tissue reactions in rats to the carcino-
genicity of a tantalum metal (Ta), as a negative foreign-body control, and to a colloidal suspen-
sion of radioactive thorium dioxide (232Th), Thorotrast, as a positive radioactive control. DU was
surgically implanted in the thigh muscles of male Wistar rats as four squares (2.5 × 2.5 × 1.5 mm
or 5.0 × 5.0 × 1.5 mm) or four pellets (2.0 × 1.0 mm diameter) per rat. Ta was similarly
implanted as four squares (5.0 × 5.0 × 1.1 mm) per rat. Thorotrast was injected at two sites in the
thigh muscles of each rat. Control rats had only a surgical implantation procedure. Each treat-
ment group included 50 rats. A connective tissue capsule formed around the metal implants, but
not around the Thorotrast. Radiographs demonstrated corrosion of the DU implants shortly after
implantation. At later times, rarifactions in the radiographic proﬁles correlated with proliferative
tissue responses. After lifetime observation, the incidence of soft tissue sarcomas increased signiﬁ-
cantly around the 5.0 × 5.0 mm squares of DU and the positive control, Thorotrast. A slightly
increased incidence occurred in rats implanted with the 2.5 × 2.5 mm DU squares and with 5.0 ×
5.0 mm squares of Ta. No tumors were seen in rats with 2.0 × 1.0 mm diameter DU pellets or in
the surgical controls. These results indicate that DU fragments of sufﬁcient size cause localized
proliferative reactions and soft tissue sarcomas that can be detected with radiography in the mus-
cles of rats. Key words: bioassay, carcinogenesis, depleted uranium, Gulf War, rats, sarcomas, soft
tissues, tantalum, Thorotrast. Environ Health Perspect 110:51–59 (2002). [Online 15 December
2001] http://ehpnet1.niehs.nih.gov/docs/2002/110p51-59hahn/abstract.htmlfactor of 10. Four implants were made per
rat. Brand et al. (9) have noted that foreign
bodies, smooth, solid pieces of metals, plas-
tics, or glass may induce tumors when
implanted in the subcutis of rats. Size (sur-
face area) was one important determinant of
this type of carcinogenicity. On the basis of
results of Alexander and Horning (10) relat-
ing carcinogenicity to foreign-body size, we
chose the maximum size of 5.0 × 5.0 mm to
minimize the occurrence of nonspecific
tumors. We used fragments (5.0 × 5.0 mm)
of tantalum (Ta) (Goodfellow Corp.,
Berwyn, PA) as a foreign-body control. In
addition, the fragments were implanted in
muscle, not subcutis, to further minimize
nonspecific tumors. Although the data are
not clear, the intramuscular route is com-
monly used to evaluate the carcinogenicity
of metals and their insoluble compounds
(11). Thorotrast, a 25% colloidal thorium
dioxide (232Th) radiographic contrast media,
was used as a positive control for radioactive
materials. The distribution, retention, and
carcinogenic effects of Thorotrast have been
summarized (12,13). Thorotrast is reported
to cause granulomas if injected perivascularly,
which occurred inadvertently in a few human
patients. A small fraction of these lesions
developed into sarcomas (14,15). The
Thorotrast used in this study was produced
by Hyden Chemical Corp (New York City,
NY) and kindly supplied by J. Humphreys
(AEA Technology, Harwell, England).
We used two sources of alpha irradiation
of muscle soft tissue in this study, one from
the metallic uranium implants and the sec-
ond from injected colloidal Thorotrast.
During the planning stages, the radiation
dose rates to tissue within range of the alpha
particles emitted by either the uranium- or
thorium-series isotopes were estimated as
follows.
Alpha spectrometric characterization of
the DU used in this study indicated that the
only alpha-emitting isotopes present in sig-
niﬁcant abundance were 238U and 234U; the
234U/238U activity ratio was 0.14. Because
the range of the uranium alpha particles in
the dense uranium metal is very small (a few
micrometers) compared to the dimensions of
the implant (e.g., 5.0 × 5.0 × 1.5 mm for the
largest implant), it was convenient to mea-
sure the alpha-particle flux being emitted
from the surfaces of the uranium metal
implants. Using a ZnS alpha-particle detec-
tor, we measured the emission rate of alpha
particles from the uranium at 4,240 disinte-
grations per minute per square centimeter of
implant surface. Assuming an average alpha
energy per emitted particle of 4.2 MeV (an
acknowledged overestimate because of the
inﬁnitely thick source geometry), we calcu-
lated a radiation dose rate averaged over a
50-µm tissue thickness surrounding the
implant (adequate to capture all of the alpha
particle energy emitted by both uranium-
and thorium-series isotopes) to be 4.1
rad/day. Although the alpha radiation dose
rate varies significantly within the 50-µm
thickness of tissue, it was nonetheless useful
to calculate this tissue-averaged dose for com-
parison with that produced by Thorotrast.
Calculating an alpha radiation dose from
injected Thorotrast was more complicated
than for the uranium metal implants because
of the complex thorium decay series of iso-
topes. When the progeny of 232Th are in
equilibrium with the parent, six alpha parti-
cles are emitted per decay of 232Th [228Th,
224Ra, 220Rn, 216Po, and either 212Bi (36%)
or 212Po (64%)]. Because the Thorotrast
used in this study was produced during the
1950s and remained in sealed vials until its
use in this study, it was reasonable to assume
that 232Th and its progeny were essentially
in equilibrium before use. However, after
intramuscular injection, it was no longer
appropriate to assume that the radioactive
progeny of 232Th remain at the injection
site, because a fraction of the nonthorium
progeny exists in the solution phase rather
than in the Thorotrast particles, and they
were transported from the injection site as
soluble species; and because newly created
progeny had finite probabilities of being
ejected from the Thorotrast particles by
recoil mechanisms, and thus also become
available for translocation as soluble atoms.
Parr et al. (16) measured the state of equilib-
rium of the progeny of 232Th in various tis-
sues from Thorotrast-injected humans, dogs,
and rats and found that the steady-state
ratios of isotopes were not related to species
for important tissues such as liver, spleen,
and red bone marrow—the major deposi-
tion/retention sites for intravenously injected
Thorotrast. Therefore, we used the following
ratios obtained from Parr et al. (16) to calcu-
late alpha radiation doses: 228Ac/228Ra =
0.97, 228Th/228Ra = 0.89, 224Ra/228Th =
0.53, 212Pb/224Ra = 0.48, and 212Bi/212Pb =
0.70. The only ratio from Parr et al. that was
not used was the 228Ra/232Th of 0.27.
Because the Thorotrast used in this study was
maintained for about 40 years in a sealed vial,
we assumed a 228Ra/232Th ratio of 1.0.
Therefore, the number of alpha particles
emitted per disintegration of 232Th was 2.77,
and the total amount of alpha-particle energy
available for deposition at the wound site was
15.74 MeV per disintegration of 232Th. To
calculate the alpha-radiation dose rate soon
after injection, we assumed a spherical geom-
etry of the injected Thorotrast, with an initial
volume of 0.025 cm3, and containing 1,510
dis min–1 232Th. This geometry yielded a
sphere of radius 1.8 mm, which, like the ura-
nium metal implants, is an infinitely thick
source for alpha particle emission. We
assumed that alpha particles could be emitted
only from a 50-µm-thick shell on the outer
surface of the Thorotrast aggregate, and that
roughly 50% of the emitted alpha particles
within this shell reached the tissue. Using
these assumptions, 230 MeV/min was
deposited in a 50-µm-thick shell of tissue
immediately in contact with the Thorotrast
deposit. This corresponds to 10.6 rad/day,
which was about 2.6 times the dose rate from
the uranium implants.
Calculations done using other assumed
tissue-source geometries showed that the
dose rate was not sensitive to the manner in
which the uranium or Thorotrast was dis-
tributed in the tissue, provided that size 
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Table 1. Physical characteristics of implants.
Volume Mass Surface area E alphaa
Type of implant Size (mm3) (mg) (mm2) (Bq)
DU (0.75 Ti) pellet 2.0 × 1.0 mmb 1.6 30 7.9 6
DU (0.75 Ti) fragment 2.5 × 2.5 × 1.5 mm 9.4 175 27.5 20
DU (0.75 Ti) fragment 5.0 × 5.0 × 1.5 mm 37.5 698 80 59
Ta fragment 5.0 × 5.0 × 1.1 mm 27.5 456 72 –
Thorotrast (injection) 0.05 mL 50 12.5 – 115
aE alpha: calculation of effective alpha-particle radioactivity emanating from the surface of the DU or Thorotrast.
bDiameter.
Table 2. Experimental design: carcinogenesis study of DU (Ti) pellets and fragments intramuscularly
implanted in Wistar rats.
Type of implant Size No. of implants Total no. of rats
DU (Ti) pellet 2.0 × 1.0 mma 45 0
DU (Ti) fragment 2.5 × 2.5 × 1.5 mm 4 50
DU (Ti) fragment 5.0 × 5.0 × 1.5 mm 4 50
Ta fragment 5.0 × 5.0 × 1.1 mm 4 50
Thorotrast (injection) 0.05 mL 2 50
Sham implant surgery NA 0 50
Total no. of rats – – 300
NA, not applicable.
aDiameter.of the uranium or Thorotrast particles
remained essentially infinitely thick. What
did change, however, was the number of
cells or the size of the tissue at risk. That is,
as the radiation source becomes more
distributed—by deformation, by fragmenta-
tion, or by dispersion amid the soft tissue—
the number of cells within range of the alpha
particles increases. For example, assuming
that the Thorotrast deposit spread out uni-
formly as a 50-µm-thick square plate in the
muscle tissue, we can calculate that the dose
rate becomes 10.9 rad/day, compared to
10.6 rad/day in the spherical geometry.
However, the volume of the tissue at risk
increased from 0.50 mm3 for the spherical
geometry to 25 mm3 for the dispersed
source—a factor of 50 greater.
We treated six groups of 50 male Wistar
rats with one of the following: DU pellets
(2.0 mm length 1.0 mm diameter), DU
fragments (2.5 × 2.5 × 1.5 mm), DU frag-
ments (5.0 × 5.0 × 1.5 mm), Thorotrast
injection (0.050 mL), Ta (5.0 × 5.0 × 1.1
mm), or sham surgery (Table 2). We pur-
chased 300 12-week-old male Wistar rats
(Charles River Laboratories, Wilmington,
MA) and maintained them in the Lovelace
Respiratory Research Institute (LRRI) ani-
mal facility. The rats were housed, two per
cage, in ﬁlter-topped polycarbonate cages on
hardwood chip bedding. Animal rooms were
maintained at 20–22°C with a relative
humidity of 40–60%. Teklad Certified
Rodent Diet (Harlan Teklad, Madison, WI)
and water were available ad libitum. Cages
and bedding were changed twice per week.
The rats were identified by tail tattoo and
placed randomly into groups of 50 rats.
Before implantation surgery, the DU
pellets, DU fragments, and Ta fragments
were weighed, cleaned to remove the oxide
formation, and sterilized. Cleaning and
sterilization comprised immersion in an
industrial detergent, rinsing in absolute ethyl
alcohol, immersion in a 50% nitric acid solu-
tion for 3 min, and rinsing with sterile water.
All pieces were stored in absolute ethyl alco-
hol to inhibit oxidation. The DU and Ta
fragments were implanted in the biceps
femoris muscle of each hind leg, two frag-
ments per leg. We used sterile procedures to
incise the skin and muscle for the implant
site and closed the incisions with two
absorbable sutures in the muscle and three
surgical wound clips in the skin. Because
Thorotrast is a colloid suspension, it was
injected into the biceps femoris muscle (two
injections of 0.05 mL, one in each hind leg).
After implantation of the fragments, the
rats were held for their life span. They were
weighed every other month. Radiographs of
the implant sites were performed on all rats
at time of implantation and at death. We
selected representative animals for radi-
ographs at 3–4 weeks after implantation.
Rats were checked twice daily, and those
moribund or in distress were euthanized
with pentobarbital. At death or euthanasia,
complete necropsies were performed with
examination of the implant sites and drain-
ing lymph nodes and of all organ systems by
opening the abdominal, thoracic, and cranial
cavities. Representative tissue sections were
taken, ﬁxed in 10% neutral buffered forma-
lin, embedded in paraffin, sectioned at 5
µm, and stained with hematoxylin and
eosin. Histologic examination was routinely
performed on the implant sites, the draining
lymph nodes, implant site neoplasms, gross
lesions that were potential neoplasms, and
the kidneys, urinary bladder, prostate, semi-
nal vesicles, testicles, epididymus, spleen,
muscle, liver, and lungs.
We analyzed one kidney and the carcass
(depelted and eviscerated) from each rat for
uranium using the Kinetic Phosphorescence
Analyzer, KPA 11 (Chemchek Instruments,
Inc., Richland, WA). The lower limit of
detection was 50 ng/L. We prepared the
samples for analysis by dry ashing at 550°C,
wet digestion in concentrated nitric acid,
treating with 3 M hydroﬂuoric acid and 0.2
M H3BO3, and dilution in 1 N nitric acid.
We compared the weights of each expo-
sure group by fitting the quadratic weights
curves for each rat using PROC NLIN (SAS
Version 8.0; SAS Institute, Cary, NC).
Three rats were not used due to incomplete
data—two from the Ta group and one from
the 2.5 × 2.5 × 1.5 mm DU group. We pro-
duced and compared parameter estimates
using analysis of variance and estimated the
survival distribution function for each group
using the nonparametric Kaplan-Meier
method. We used the log rank and the
Wilcoxon tests to evaluate homogeneity
across all groups. If homogeneity was
rejected (p < 0.05) by either test, pair-wise
comparisons were made (SAS Proc, Version
8). We compared the differences in the
tumor incidences among the various expo-
sure groups using Fischer’s exact test (Sigma
Stat for Windows Version 1.0; SPSS Science,
Chicago, IL).
Results
The body weights for the various exposure
groups are shown in Figure 1. The increase
in weight in early life with a decrease in later
life is a pattern often observed among male
rats (17). None of these weight curves is sta-
tistically different from the sham control
weight curve.
The survival of the various exposure
groups did not differ signiﬁcantly (Figure 2).
The median survival time for the six groups
ranged from 576 to 620 days after implanta-
tion. The similarity of the survival of the six
groups eliminated a competing risk when
determining tumor incidence.
The radiographic appearance of the
implanted DU fragments changed markedly
during the ﬁrst year. At the time of implan-
tation, the fragments were smooth squares
with regular, sharp, well-defined edges
(Figure 3A). At 21 days after implantation,
small, dense blebs extended from the edges
of the fragments, making them appear larger
than at time of implantation. The jagged
appearance disrupted the sharp proﬁle of the
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Figure 2. Survival of rats implanted with DU or Ta fragments or injected with
Thorotrast compared with sham controls.
Figure 1. Body weights of rats implanted with DU or Ta fragments or injected
with Thorotrast, compared with sham controls.
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DU 5 x 5mmfragments (Figure 3B). At 1 year after
implantation, the radiographic proﬁles of the
fragments were rounded, with no corners
and a ﬁne, jagged edge (Figure 3C). At time
of death, many of the proﬁles were enlarged
up to 1.5 times in linear dimensions. These
radiographic changes were related to surface
corrosion of the DU in vivo and capsule for-
mation. In contrast, the profiles of the Ta
fragments were smooth at all times with
sharp, well-defined edges and did not
increase in size with time (Figures 4A and
B). Initially, the Thorotrast injections gave a
spherical radiographic outline (Figure 5A).
At 4 weeks the proﬁle was irregular and dif-
fuse, with no distinct boundary (Figure 5B).
The proﬁles had a similar appearance at 1.5
years after injection (Figure 5C).
The implants of DU or Ta were encap-
sulated with connective tissue at the time of
death. Most of the fragments were located in
the muscles where they were originally
implanted, but some had migrated to the
loose connective tissues between the muscles
of the leg. The injected Thorotrast did not
induce capsule formation, but was localized
in and around the muscles causing a tan dis-
coloration. Before histologic sectioning of
the capsules, the tissues were fixed in 10%
neutral buffered formalin, and the implants
were removed. The Ta fragments slipped
easily from the capsules. The DU fragments,
however, adhered to the capsules and were
difﬁcult to remove from the tissues. The sur-
faces of these fragments were friable. A
black, gritty layer of granular material was
left on the inner surface of the capsule.
The capsules around the DU implants
were characterized histologically by ﬁbrosis,
inﬂammation, degeneration, and mineraliza-
tion (Figure 6A). Around the large DU
implants, the capsules were up to 0.5 mm
thick and composed of dense ﬁbrous tissue.
More typically, the capsules were 0.1–0.2 mm
thick. Shards of black material were embed-
ded in the ﬁbrous tissue capsules around the
medium and large fragments. Smaller parti-
cles in a range of sizes (< 4 µm) were found in
the capsule wall around all sizes of DU
implants. Chronic inflammatory cells and
particle-laden macrophages were frequently
scattered throughout the capsule wall of the
DU implants. Occasionally foreign-body
giant cells were found. However, the amount
of chronic inﬂammation in and around the
capsules was generally similar among DU
implants of all sizes. Degeneration of the
ﬁbrous tissue in the capsule wall was frequent
at the interface with the implant. With this
reaction, the tissue on the inner surface of the
capsule was devitalized and necrotic. The
lumen of the capsules contained necrotic
and proteinaceous debris, scattered acute
inﬂammatory cells, and varying amounts of
black shards or particles. The particles were
contained in macrophages or free in the
lumen as amorphous clumps of various sizes.
Mineralization of necrotic debris or devital-
ized fibrous tissue on the inner wall of the
capsules was common.
The capsules around the Ta implants were
characterized by ﬁbrosis with little inﬂamma-
tion and no degeneration or mineralization
(Figure 6B). The capsule walls were less than
0.1 mm thick with a smooth inner surface.
No shards or particles were present.
The Thorotrast lesion was an accumula-
tion of macrophages between muscle fibers
and adjacent to muscles (Figure 6C). The
macrophages were ﬁlled with a tan, coarsely
granular material. These macrophages were
not associated with inﬂammation or ﬁbrosis.
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Figure 4. Radiograph of 5.0 × 5.0 × 1.1 mm Ta fragments. (A) 10 weeks after implantation (rat B020-6024);
(B) 2 years after implantation (rat N026-6036).
Figure 3. Radiograph of 5.0 × 5.0 × 1.5 mm DU fragments in rat R097-604. (A) On day of implantation (radio-
opaque wound clips visible on the skin); (B) 3 weeks after implantation; (C) 1 year after implantation.Soft tissue tumors of various types were
associated with many of the implants. The
tumors were classiﬁed histologically accord-
ing to criteria of the Society of Toxicologic
Pathologists (18) (Table 3). The most com-
monly found tumor types were malignant
fibrous histiocytomas and fibrosarcomas.
The three osteosarcomas were not associated
with the skeleton. Although there was a
higher number of fibrosarcomas in the
Thorotrast-treated rats and a broader range
of tumors in the DU-treated rats, we could
not attribute a specific tumor type to a
specific treatment. All of the tumors, how-
ever, were most likely derived from primitive
mesenchymal stem cells (19).
All tumors were in the soft tissues of the
hind legs, directly associated with the
implanted DU or Ta fragments or the
injected Thorotrast. Three tumors were
localized to the wall of the fibrous capsules
surrounding the implants. In other tumors,
black shards, particles of implanted frag-
ments, or Thorotrast-filled macrophages
could be seen scattered through most of the
tumor tissues. These histologic ﬁndings lend
further credence to the association of the
implants with the tumors.
Biologically, these tumors were moder-
ately aggressive (Table 4). Many were grow-
ing rapidly, expanding in size from barely
palpable to 3 or 4 cm in 2 weeks. However,
none invaded bone and only one ulcerated
the skin. One metastasized to an iliac lymph
node and another metastasized widely.
Twenty-nine of the 40 were large enough to
result in euthanasia. The other 11 were dis-
covered at necropsy or in tissue sections of
the capsules surrounding the implants.
The incidence of the tumors increased in
the rats with the largest DU implants when
compared with the sham or foreign-body
(Ta) controls (Figure 6). The difference was
signiﬁcant (p ≤ 0.028) with a Fischer’s exact
test. The radioactive-materials control ani-
mals, injected with Thorotrast, had a signiﬁ-
cant increase in number of tumors compared
with the DU-implanted rats (p < 0.0014). In
addition, there was a fragment size-related
response in the DU-treated rats. The
response could not be explained by physical
surface area alone because the tumor inci-
dence with the Ta implants of similar size
was much lower. There was, however, a cor-
relation with the initial surface alpha
radioactivity (Figure 7). This initial activity
was calculated from the physical characteris-
tics of the DU fragments and the Thorotrast
colloid. The injected colloid was considered
a sphere for calculation purposes. Radio-
graphs showed that the physical shape of the
fragments and the colloid changed within 4
weeks after implantation. Thus, the surface
alpha radioactivity changed with time as the
shape of the implants changed.
Comparison of the radiographs of the
DU-associated lesions with the histologic
appearance of the lesions showed a correlation.
After being implanted for a year or more, all of
the DU fragments were enlarged and rounded
in radiographic proﬁle (Figure 8A). These fea-
tures generally correlated with a dense, con-
nective tissue capsule. However, disruption of
the smooth-edge proﬁle and focal loss of den-
sity in the DU fragment were associated with
proliferative lesions or small tumors in the
capsules (Figure 8B). Disintegration and
breakup of the DU fragment were apparent
on radiographs when frank tumors were pre-
sent. On the histologic sections, black shards
of DU could be seen throughout the tumor
tissue (Figure 8C). These radiographic changes
associated with the DU fragments may be
important indicators of accompanying prolif-
erative lesions and may have prognostic value
in clinical evaluations.
The tumors in tissues not associated with
the implant sites are noted in Table 5. There
was no signiﬁcant increase related to exposure
in any tissue routinely sampled or in tissue
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Figure 6. Tissue reaction to implants. (A) DU fragment: black shards of corroded DU lined the thick cellu-
lar ﬁbrotic capsule surrounding the fragment 520 days after implantation. (B) Ta fragment: a thin acellular
ﬁbrotic capsule with no metal pieces present 603 days after implantation. (C) Thorotrast injection: no cap-
sule or inﬂammation; Thorotrast-laden macrophages inﬁltrated skeletal muscle 792 days after injection.
Figure 5. Radiograph of Thorotrast injection in rat I047-6037. (A) On day of injection; (B) 4 weeks after
injection; (C) 1.5 years after injection.
Table 3. Number of implant-associated soft tissue tumors. 
Tumor types Thorotrast DU Ta Surgical control
Benign tumors
Benign ﬁbrous histiocytoma 0 1 0 0
Fibroma 0 1a 00
Granular cell myoblastoma 1 0 0 0
Malignant tumors
Malignant ﬁbrous histiocytoma 13 7a 20
Fibrosarcoma 10 2 0 0
Osteosarcoma 1 2 0 0
aOne rat had two tumors associated with separate implants.samples when gross lesions were noted. An
increased incidence of renal tumors was seen
only in those rats with implants of DU. The
incidence was not statistically significant,
however, even when all groups implanted
with DU fragments combined were com-
pared with all three control groups (sham,
Ta, Thorotrast) combined (p > 0.06 with
Fischer’s exact test). The renal tumors were
classiﬁed as tubular cell adenoma (1), tubular
cell adenocarcinoma (3), and sarcoma (1).
Radiochemistry of the kidney and carcass
(Table 6) showed that the concentration of
uranium in the kidney at time of death var-
ied within the various groups as shown by
the wide standard deviations. The mean renal
concentrations in the two largest fragments
were not significantly different, despite the
differences in mass (~3×) and surface area
(~2×) of the fragments. The concentration of
uranium in the carcass showed an increased
concentration with the increased mass of ura-
nium. The fraction of the embedded frag-
ments found in the kidney decreased with
mass and surface area. In contrast, the frac-
tion of the fragments in the carcass was
nearly constant among the three groups.
Discussion
These ﬁndings clearly indicate that DU frag-
ments of sufﬁcient size were carcinogenic in
the muscles of rats. The incidence of soft tis-
sue neoplasms was significantly greater in
rats with DU implants than in rats with for-
eign-body control (Ta) implants. The neo-
plasms induced were associated directly with
the implants; no increase in tumors was
noted elsewhere in the body.
The validity of injecting or implanting
materials and compounds in the subcutis or
muscles of rodents to test for carcinogenicity
in humans has been questioned (11). The
concern is that tissue reactions in rodents are
seen with many materials, may be nonspeciﬁc,
and may not occur in humans. Several com-
pounds or materials injected or implanted in
the subcutis of rats caused localized cancer but
were later determined not to cause cancer in
humans. Examples are certain food colorings
(20), iron dextran (21), and silicone implants
with breast cancer (3). In addition, seemingly
innocuous materials placed in the subcutis
have caused localized cancers—materials such
as aluminum foil, glass sheets, and methyl cel-
lulose ﬁlters of a certain size (9).
Foreign-body carcinogenesis has been
induced experimentally in the soft tissues of
rats by a number of sheet-like implanted
materials, indicating that rats are sensitive to
this type of carcinogenesis (22–25). The
physical nature of the sheets was more
important than the chemical nature in
determining carcinogenesis (9). The size of
the sheet (> ~ 5.0 × 5.0 mm), physical
smoothness (a noncorroded surface), and con-
tinuity (no holes in the sheet) were three key
physical parameters. A sheet of sufﬁcient size
to be carcinogenic could be rendered noncar-
cinogenic by cutting it into smaller pieces,
perforating it with numerous holes, or rough-
ening the surface. The degree of inflamma-
tion also played a role. The greater the
inflammatory response or the longer it per-
sisted in the tissues, the less likely the sheetlike
material would induce soft tissue tumors.
Tests using rats, however, can be reason-
able predictors of the carcinogenicity of
materials in humans. Numerous metal pow-
ders and metal implants have been tested by
injection or embedding in the muscles (not
the subcutis) of rats (Table 7). A range of
localized tissue responses was noted related
to chemical composition or size. These ﬁnd-
ings indicated that not all metals injected or
implanted in the muscles of rats induce
localized tumors and that the elemental
composition was important for metal pow-
ders, and the size (or surface area) was
important for the metal squares, discs, or
rods.
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Table 4. Biologic characteristics of implant-associated soft tissue tumors.
Total Relationship Median
no. of to death  No. with survival Range
Tumor types tumors COD INC metastasis time (days) (days)
Benign tumors
Benign ﬁbrous histiocytoma 1 0 1 0 515 –
Fibroma 1 0 1 0 601 –
Granular cell myoblastoma 1 0 1 0 769 –
Malignant tumors
Malignant ﬁbrous histiocytoma 22 18 4 0 668 518–987
Fibrosarcoma 12 8 4 1 614 515–853
Osteosarcoma 3 3 0 1 572 493–645
Abbreviations: COD, cause of death or euthanasia; INC, incidental.
Figure 7. Incidence of soft tissue tumors in rats implanted with DU, Ta, or Thorotrast. The incidence of
tumors in rats with 5.0 × 5.0 mm DU fragments signiﬁcantly increased over the incidence in rats with Ta
fragments of the same size. The positive control, Thorotrast, produced the highest incidence of tumors.
Thorotrast > DU 5.0 × 5.0 mm, p = 0.0014; DU 5.0 × 5.0 mm > sham control, p = 0.0012; DU 5.0 × 5.0 mm > Ta,
p = 0.028 (Fischer’s exact test). 
50
40
30
20
10
5
2.5
0
02 04 06 08 0100 120 140 160 180
I
n
c
i
d
e
n
c
e
 
o
f
 
t
u
m
o
r
s
 
(
%
)
(
N
o
.
 
r
a
t
s
 
w
i
t
h
 
t
u
m
o
r
s
/
n
o
.
 
r
a
t
s
 
i
m
p
l
a
n
t
e
d
 
×
 
1
0
0
)
Surface area (mm2) (DU and Ta only)
0 15 30 45 60 75 90 105 120 135
Alpha activity (Bq) (DU and Thorotrast only)
Thorotrast
Ta
DU (Ti)
Surgical control = 0%For the metal powders, the incidence of
localized tumors ranged from 0 to 100%. The
highest incidence was with nickel, a known
human carcinogen. The lowest incidences
were with metals with low carcinogenicity,
titanium, lead, and chromium metal. For
implanted materials, there appeared to be a
relationship to the size or surface area. For
example, all of the metals with surface areas of
44 mm2 or less did not induce localized
tumors, except DU 2.5 × 2.5 mm fragments
with 28 mm2. The stainless steel implant with
75 mm2 had a tumor incidence of 5%, essen-
tially the same as the tumor incidence for Ta
fragments with 72 mm2. On the other hand,
the DU 5.0 × 5.0 mm fragments with nearly
the same surface area of 80 mm2 had a tumor
incidence of 18%.
The finding of DU fragment carcino-
genicity in rats does not indicate, however,
that DU fragments are necessarily carcino-
genic in humans. Artiﬁcial implants and acci-
dental foreign-body material are associated
with occasional soft tissue sarcomas in
humans, although precise figures are not
available (35). It has been argued that the rate
must be low because of the small number of
implant-associated soft tissue sarcomas
reported in the literature despite the frequent
use of various implants for medical purposes
(36). The sole epidemiologic study of artiﬁcial
implants and soft tissue sarcomas used a
case–control approach with a population of
217 Vietnam veterans with soft tissue sarco-
mas (37). Respondents noted whether they
had an implant of an artificial joint, pin,
plate, staple, screw, or any other metal or plas-
tic implant. None had an artiﬁcial joint. In
that study, no association was found between
soft tissue sarcomas and the implants.
Uranium compounds have not been
demonstrated to cause cancers in humans,
even as a result of high occupational exposures
(38). Over 30,000 persons occupationally
exposed in U.S. Department of Energy con-
tractor laboratories have been followed in
epidemiologic studies with no health effects
reported. These exposures occurred primar-
ily by inhalation or ingestion, not by the
embedding of metal fragments. Thus, the
situation of the Gulf War veterans who were
wounded with DU fragments is unique.
The mechanism by which DU fragments
induced localized cancers in rats may be
important in determining the carcinogenic-
ity of DU fragments in humans. The Ta
fragments used here fit two criteria for for-
eign-body carcinogenesis: smoothness and
continuity of the sheet. Little inﬂammation
was induced by the Ta fragments, and the
ﬁbrous capsule was thinner than the capsule
around the DU fragments. The size (5.0 ×
5.0 mm) was smaller than that reported nec-
essary for foreign-body carcinogenesis in rats
(10). However, the tumor incidence was
essentially the same as that for stainless steel
disc implants of similar surface area (Table
7). The soft tissue tumors related to the Ta
fragments in this study were most likely
induced by the foreign-body mechanism
described in the rat (9).
The Thorotrast injections induced a
high incidence of soft tissue sarcomas, indi-
cating that rats are sensitive to carcinogenesis
from radioactive materials implanted in the
muscles. The 232Th in Thorotrast is radioac-
tive. The radioactive decay chain from 232Th
produces about six alpha particles per disin-
tegration with an average total energy of
about 26 MeV. The calculated radiation
dose to the local tissue around the injection
site in the rats is about 0.5 Gy per year when
the injection is a sphere with the volume of
0.50 mm3. The Thorotrast did not stay in a
sphere, but over a period of weeks spread out
between the muscle bundles, where it
remained for years. Thus, the calculated
radiation dose is only an estimate, but is
probably low compared to the real value.
This annual dose is lower than the estimate
of > 1 Gy per year for the human patients
that had Thorotrast inadvertently injected
into the paravascular soft tissues (15). These
individuals developed intense sclerotic
lesions in the soft tissues, and one developed
a soft tissue sarcoma. In the Wistar rats,
essentially no inﬂammatory reaction, ﬁbrotic
reaction, or proliferative lesion was seen in
response to the injected Thorotrast.
However, the earliest deaths where tissues
could be examined were at about 300 days
after injection, so an early, transient inﬂam-
matory reaction may have been overlooked.
The DU fragments did not appear to
cause soft tissue sarcomas by the foreign-body
mechanism so well described in rats (9,39).
The surface of the DU fragments, although
initially smooth, quickly became corroded
and roughened. In addition, the histologic
reaction to DU fragments showed much
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Figure 8. Correlation of radiographic appearance with histologic appearance. (A) Thick ﬁbrotic capsule
with shards of corroded DU in lumen; (B) thick cellular capsule lined by squamous metaplasia, particles,
and shards of corroded DU in wall and lumen; (C) particles and shards of disintegrated DU fragment scat-
tered throughout a soft tissue sarcoma.more inﬂammation and ﬁbrosis than did the
lesions associated with Ta fragments. The Ta
fragments used in this study and the stainless
steel discs used in previous studies (26) initi-
ated tumors by the foreign-body mechanism
and had a much lower incidence of sarcomas.
These differences between the reactions and
tumor incidence of DU and Ta fragments or
stainless steel discs indicate that something
more than foreign-body carcinogenesis is
occurring with DU-fragment carcinogenesis.
A radiation mechanism may have played a
role in the carcinogenicity of the DU frag-
ments. One indication of this was the
increased incidence of soft tissue sarcomas,
which was correlated most closely with the
increased surface alpha radioactivity of the
implanted materials than with the surface area
(Figure 7). On the other hand, Thorotrast,
which initiated tumors by a radiation mecha-
nism, elicited essentially no reaction in the tis-
sues, a distinct difference from the DU
fragments.
The mechanism by which DU fragments
induced soft tissue sarcomas is uncertain.
One striking feature of the reaction is the
corrosion of the DU in the tissues and the
intensity of the inflammatory and fibrotic
response to the fragments. The response is
similar to the local tissue reactions produced
by food coloring and other soluble com-
pounds repeatedly injected subcutaneously in
rats (20). Compounds that produced tissue
destruction with subsequent dense collagen
formation invariably induced soft tissue sarco-
mas. Physicochemical properties closely
related to tissue destruction were marked sur-
face activity, lipid solubility, and protein-
binding ability (40). These properties are
directly related not to chemical carcinogenesis
but to a continual cellular damage and repair
mechanism. A similar process may occur with
DU-associated soft tissue sarcomas.
Understanding the mechanism by which
DU fragments induce tumors in rats is
important in determining the likelihood of a
similar mechanism occurring in humans.
Further research will be required to deter-
mine the importance of various mechanisms:
foreign body, radiation, chemical, or contin-
ued cell damage and repair.
The lack of a signiﬁcantly increased inci-
dence of tumors other than at the site of the
implants indicates that uranium is not an
effective systemic carcinogen. The tumor
types and incidence were generally similar to
those previously described for Wistar rats
(41,42). The total incidence of primary renal
tumors was 4% in each of two DU(Ti) frag-
ment groups (5.0 × 5.0 mm and 2.5 × 2.5
mm). This total incidence was high com-
pared to that previously reported in Wistar
rats (41). The increase, however, was not sta-
tistically signiﬁcant. In addition, the types of
renal tumors found were similar to those
occurring spontaneously in Wistar rats.
Interestingly, the concentrations of uranium
in the kidneys of these two groups were
nearly the same, 10.5 and 8.95 µg U/g kid-
ney (Table 6). However, there was not a
good correlation of renal uranium concen-
tration and tumor incidence. The renal ura-
nium concentration in the rats with renal
tumors ranged from 1.19 to 32.2 µg/kidney.
The above points indicate that the
increased incidence of renal tumors is not
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Table 7. Carcinogenesis studies of metals implanted or injected in the muscles of rats.
Size
(mm diam. Mass or Tumor
Material Form × length) surface area incidencea Reference
DU–metal Implant–pellet 2.0 × 1.0 7.9 mm2 0/50 This study
DU–metal Implant–square 2.5 × 2.5 × 1.5 28 mm2 3/50 This study
DU–metal Implant–square 5.0 × 5.0 × 1.5 80 mm2 9/49 This study
Tantalum Implant–square 5.0 × 5.0 × 1.1 72 mm2 2/50 This study
Stainless steel Implant–rod 8.0 × 1.6 44 mm2 0/34 (26)
Vitallium–cast or wrought Implant–rod 8.0 × 1.6 44 mm2 0/49 (26)
Titanium–unalloyed Implant–rod 8.0 × 1.6 44 mm2 0/24 (26)
Titanium–alloy Implant–rod 8.0 × 1.6 44 mm2 0/22 (26)
Stainless steel Implant–disc 4.0 × 1.5 25 mm2 0/40 (27)
Stainless steel Implant–disc 12.0 × 1.5 75 mm2 2/37 (27)
Stainless steel Implant–disc 18.0 × 1.5 113 mm2 5/42 (27)
CoCrMo–metal alloy Powder 28 mg 0/142 (28)
CoCrMo–metal alloy Powder 28 mg 27/72 (29)
NiFe–metal Powder 14 mg 0/20 (30)
Cr–metal Powder 4 mg 0/20 (30)
Pb–metal Powder 95 mg total 1/37 (31)
Ti–metal Powder 23 mg in females or  2/50 (32)
39 mg in males
Co–metal Powder 28 mg 17/30 (33)
Ni–metal Powder 25 mg total 38/50 (31)
Ni–metal Powder 28 mg 10/10 (34)
aAt site of implant or injection.
Table 5. Number of benign and malignant tumors not associated with implant site.
DU DU DU
Ta 2.0 × 1.0 2.5 × 2.5 5.0 × 5.0
Site of tumor Sham fragment Thorotrast mm mm mm
Number of rats examined 50 50 50 50 50 49
Muscle 0/0a 0/1 0/0 0/0 0/1 0/0
Kidney 0/0 0/0 0/0 0/1 1/1 0/2
Urinary Bladder 0/0 0/2 0/0 0/0 0/1 0/0
Testes 5/0 7/0 3/0 3/0 5/0 5/0
Prostate 0/0 0/0 0/0 0/0 0/0 0/0
Epididymis 0/0 0/0 0/0 0/0 0/0 0/0
Seminal Vesicle 0/0 0/0 0/0 0/0 0/0 0/0
Liver 4/0 4/2 1/1 1/1 4/1 1/2
Spleen 0/6 0/4 0/1 0/2 0/7 0/4
Lung 0/0 0/0 0/0 0/0 0/0 1/0
Number of rats examinedb
Bone 0/0 0/0 0/0 0/2 0/0 0/0
Adrenal 1/2 2/1 0/3 0/1 0/2 5/1
Thyroid 1/0 2/2 0/1 3/0 2/0 0/0
Pituitary 6/5 6/2 18/1 6/0 9/3 4/1
Mammary Gland 3/0 3/1 3/0 2/0 4/0 1/0
Pancreas 1/0 2/1 0/4 2/0 4/0 1/2
Skin 7/1 5/2 5/3 5/3 4/1 7/1
aNumber of benign tumors/number of malignant tumors. bVaries; tissues were sampled if gross lesions were present.
Table 6. Concentration of uranium in kidney and carcass at death.
Concentration of U Kidney/ Fraction of fragment in tissue
DU fragment (µg U/g tissue ± SD) carcass U (fraction ± SD)
group Kidney Carcass concentration Kidney Carcass
2.0 × 1.0 mm 2.72 ± 3.03 0.20 ± 0.18 13 1.03 × 10–4 3.47 × 10–4
± 8.29 × 10–5 ±2 . 95 × 10–4
2.5 × 2.5 mm 8.95 ± 5.38 1.28 ± 1.18 7.0 8.03 × 10–5 5.17 × 10–4
± 3.87 × 10–5 ±3 . 02 × 10–4
5.0 × 5.0 mm 10.5 ± 6.92 5.20 ± 4.75 2.0 2.07 × 10–5 4.73 × 10–4
± 1.07 × 10–5 ±4 . 29 × 10–4Articles • DU-induced soft tissue sarcomas in rats
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statistically significant and is probably not
biologically significant either. However, a
previous report that urine from DU-bearing
rats has an increased mutagenic activity (6)
does require that this ﬁnding of an increased
renal tumor incidence be investigated further.
The implications of these ﬁndings for the
medical management and risk assessment
among wounded veterans are unclear. The
ﬁnding of DU implant-associated soft tissue
sarcomas in rats indicates a carcinogenic
potential for DU fragments. However, given
the ﬁndings in the controls in this study and
the reports in the literature (3,9), rats are
more sensitive to foreign-body and radiation
carcinogenesis than are humans. The ﬁndings
from these studies cannot be directly extrapo-
lated to humans. More information is needed
before risk estimates for humans with embed-
ded DU fragments can be determined.
Prudence, however, requires caution in
the medical management of wounded indi-
viduals. It may be prudent to use radiogra-
phy to monitor embedded fragments in
wounded individuals. Changes in the radi-
ographic proﬁles of the fragments that show
focal loss or breakdown and changes associ-
ated with proliferative lesions in the rats may
indicate removal of speciﬁc fragments.
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